CIK 0001438533 · Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 262383102
- Phone
- 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $79,812,468
- in 11 filings, $79.8M under 10b5-1 plans
Net −$79,812,468. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-31 | Heerma Peter CHIEF COMMERCIAL OFFICER | Grant or award | +26,120 | 139,133 | ||
| 2026-01-31 | Heerma Peter CHIEF COMMERCIAL OFFICER | Grant or award · Employee stock option (right to buy) | +69,640 | 69,640 | ||
| 2026-01-31 | Dube Eric M CHIEF EXECUTIVE OFFICER | Grant or award 10b5-1 | +113,800 | 532,973 | ||
| 2026-01-31 | Dube Eric M CHIEF EXECUTIVE OFFICER | Grant or award · Employee stock option (right to buy) 10b5-1 | +303,600 | 303,600 | ||
| 2026-01-31 | ROTE WILLIAM E. Chief Research Officer | Grant or award 10b5-1 | +20,090 | 121,533 | ||
| 2026-01-31 | ROTE WILLIAM E. Chief Research Officer | Grant or award · Employee stock option (right to buy) 10b5-1 | +53,570 | 53,570 | ||
| 2026-01-31 | REED ELIZABETH E Chief Legal Officer and GC | Grant or award | +25,110 | 115,380 | ||
| 2026-01-31 | REED ELIZABETH E Chief Legal Officer and GC | Grant or award · Employee stock option (right to buy) | +66,960 | 66,960 | ||
| 2026-01-27 | Dube Eric M CHIEF EXECUTIVE OFFICER | Option exercise 10b5-1 | +51,865 | $15.46 | $802K | 471,038 |
| 2026-01-27 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −51,865 | $30.10 | $1.6M | 419,173 |
| 2026-01-27 | Dube Eric M CHIEF EXECUTIVE OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −51,865 | 120,000 | ||
| 2026-01-23 | Dube Eric M CHIEF EXECUTIVE OFFICER | Option exercise 10b5-1 | +8,135 | $15.46 | $126K | 427,308 |
| 2026-01-23 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −8,135 | $30.01 | $244K | 419,173 |
| 2026-01-23 | Dube Eric M CHIEF EXECUTIVE OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −8,135 | 171,865 | ||
| 2026-01-20 | REED ELIZABETH E Chief Legal Officer and GC | Option exercise 10b5-1 | +10,000 | $19.08 | $191K | 100,270 |
| 2026-01-20 | REED ELIZABETH E Chief Legal Officer and GC | Sale 10b5-1 | −10,000 | $27.34 | $273K | 90,270 |
| 2026-01-20 | REED ELIZABETH E Chief Legal Officer and GC | Option exercise · Employee stock option (right to buy) 10b5-1 | −10,000 | 30,000 | ||
| 2026-01-06 | Inrig Jula CHIEF MEDICAL OFFICER | Sale 10b5-1 | −445 | $37.75 | $17K | 86,311 |
| 2026-01-05 | Inrig Jula CHIEF MEDICAL OFFICER | Sale 10b5-1 | −2,031 | $40.18 | $82K | 86,756 |
| 2025-12-24 | Inrig Jula CHIEF MEDICAL OFFICER | Option exercise 10b5-1 | +15,000 | $8.93 | $134K | 103,787 |
Page 14 of 51 · 1,020 trades